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Summary Incomplete case finding is a problem in epidemiological studies of
epilepsy. We tried to optimize case ascertainment by combining information from
individual interviews and medical records. During 2 years, 1838 inhabitants of Va˚ga˚,
Norway, aged 18—65 (88.6% of the target population) were interviewed as part of an
epidemiological study of headache. Individuals with learning disability, mental dis-
orders and dementia were excluded. One question concerning epilepsy was presented
to 1793 consecutive cases (mean age 35, males 49%): ‘‘Have you ever had convulsions,
epileptic fits or other epileptic symptoms?’’ The medical records of the 133 subjects
who acknowledged this possibility were reviewed, and telephone interviews were
performed when needed. A diagnosis of epilepsy had been made in 41 subjects.
Twenty-one were treated with antiepileptic drugs, of whom 12 had had seizures
within the last 5 years. By this unique method of case ascertainment, the prevalence
of epilepsy in adults (cases under treatment) was 1.2%, and of active cases 0.7%,
despite the fact that high-risk groups for epilepsy, such as elderly people and
individuals with cognitive deficits, were excluded. Although these findings were
derived from a small population in a circumscribed rural area, they suggest that
the true prevalence of epilepsymay be higher than reflected inmany previous studies.
# 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Epilepsy is one of the most common chronic neuro-
logical disorders world-wide. The symptoms are
limited to short-lasting attacks, which even in
patients with intractable seizures occupy only minor* Corresponding author. Tel.: +47 72575075; fax: +47 72575774.
E-mail address: eylert.brodtkorb@ntnu.no (E. Brodtkorb).
1059-1311/$ — see front matter # 2008 British Epilepsy Association
doi:10.1016/j.seizure.2008.03.005parts of their total lives. The diagnosis is associated
with prejudice and myths, and some victims endea-
vour to keep it secret. A large number of epidemio-
logical studies have been undertaken to assess the
population-based prevalence of epilepsy in various
parts of the world (see1—3). However, a range of
methodological shortcomings hamper these surveys.
Study designs differ considerably. Diversities of
sources for case identification, heterogeneity of. Published by Elsevier Ltd. All rights reserved.
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Table 1 Diagnoses in 133 subjects who acknowledged
a possible ‘‘history of convulsions, epileptic fits or
other epileptic symptoms’’ (numbers)
Epilepsy ever (41)
Active (12)
In remission with treatment (9)
In remission, treatment withdrawn (18)
In remission, never treated (2)
Single unprovoked seizures (4)
Situation-related seizures (20)
Febrile seizures in childhood (14)clinical manifestations and differences regarding
prognosis may influence the findings. Problems con-
cerning definition and accurate diagnosis are often
prevailing.4 Cases are also missed because some
sufferers conceal their condition and do not seek
appropriate medical help or do not comply with
treatment and follow-up.
We have tried to optimize case ascertainment by
individual interviews in a population of a small, rural
community in Norway.Alcohol related (3)
Hypoglycemia in diabetes (2)
Other (1)
Psychogenic non-epileptic seizures (1)
Apparent syncopes (35)
Miscellaneous (32)
Probably hyperventilation induced (5)
Transitory ischemic attacks (5)
Migraine aura (1)
Unclear and other episodes (21)Methods
The study was carried out as part of an epidemio-
logical study of headache in the Va˚ga˚ community in
southern Norway. The design of this study has pre-
viously been described in detail.5,6 A short version is
given in this context.
During a 2-year period beginning in 1995, a total
of 1838 inhabitants in the age range18—65 (males
49%) met for an individual examination by one single
investigator (OS). The recruited individuals com-
prised 88.6% of the invited target population
(n = 2075) at the start of the study. The examiner
had been brought up in the parish and knows the
local conditions well. Inhabitants with learning dis-
ability, mental disorders and dementia were
excluded. The participants underwent a semi-struc-
tured interview concerning headache and a neuro-
logical/physical examination. In addition, one single
question concerning epilepsy was presented to 1793
consecutive cases (mean age 35, males 49%): ‘‘Have
you ever had convulsions, epileptic fits or other
epileptic symptoms?’’ The Health Centre medical
records of those who acknowledged possible epilep-
tic symptoms were reviewed (by E.B.), and tele-
phone interviews were performed when needed.
The study area has a relatively stable, rural popula-Table 2 Patients with active epilepsy in Va˚ga˚
Patient number Sex Age Onset age Sei
1 F 49 0 CP,
2 F 36 7 SP,
3 M 19 15 CP
4 M 36 19 SP,
5 F 24 20 CP,
6 M 38 25 CP,
7 M 31 26 GT
8 M 37 28 GT
9 M 36 33 GT
10 M 60 43 GT
11 F 61 45 CP,
12 F 54 51 GT
F, female; M, male; CP, complex partial; GTC, generalized tonic-cltion. It is served by general practitioners with a basis
in the national health care. Relevant medical
reports from hospitals and specialists are usually
available for all inhabitants at the communal health
centre.
The following definitions were adopted from
the International League against epilepsy.4 Active
epilepsy means fulfilment of the criteria for epi-
lepsy and a minimum of one seizure in the pre-
vious 5 years. Cases under treatment are
individuals with the correct diagnosis of epilepsy
receiving antiepileptic drugs (AEDs), regardless of
seizure control.
Informed consent was given by all patients. The
study was as a whole recommended by the Regional
Committee for Ethics in Medical Research and by the
Norwegian Data Inspectorate.zure types Epilepsy syndrome Etiology
GTC Partial Cryptogenic
GTC Partial Cryptogenic
Partial Cryptogenic
GTC Partial Encephalitis
GTC Partial Cryptogenic
GTC Partial Cryptogenic
C Partial Cryptogenic
C Partial Cryptogenic
C Partial Post-traumatic
C Unclassified Unknown
GTC Partial Post-traumatic
C Partial Post-traumatic
onic; SP, simple partial.
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Table 3 Patients with epilepsy in remission with treatment in Va˚ga˚
Patient
number
Sex Age Onset age Age of last
seizure
Seizure
types
Epilepsy
syndrome
Etiology
1 F 57 11 40a GTC Partial Cryptogenic
2 M 22 14 16 GTC Generalized Idiopathic
3 M 56 15 19 SP, GTC Partial Post-traumatic
4 F 49 16 31 GTC Generalized Idiopathic
5 M 46 18 36a GTC Generalized Idiopathic
6 M 38 33 33 SP, GTC Partial Cryptogenic
7 M 41 35 36 GTC Partial Cryptogenic
8 M 59 36 39 GTC Partial Post-traumatic
9 F 47 41 42 GTC Partial Cryptogenic
F, female; M, male; GTC, generalized tonic-clonic; SP, simple partial.
a Recurrence after AED withdrawal.Results
As many as 133 inhabitants confirmed that a history
of convulsions, epileptic fits or other epileptic symp-
toms could not be excluded. Nevertheless, only 41
(mean age 42, males 51%) were diagnosed as ever
having had epilepsy (2.3%) on the basis of medical
records, supported by telephone interviews in 30
patients. The remaining subjects were categorized
with a range of other diagnoses (Table 1).
A total of 21 individuals were treated with AEDs
(mean age 43, males 62%), of whom 12 had active
epilepsy (mean age 40, males 58%) with seizures
within the last 5 years (Tables 2 and 3). The crude
prevalence of definite epilepsy (cases under treat-
ment) was estimated to be 11.7/1000 in the inves-
tigated population. Prevalence of active epilepsy
was 6.7/1000. Twenty patients in remission were
not treated at the time of examination; two indivi-
duals with nocturnal seizures limited to early
school-years had never received AEDs (Table 1).Discussion
By this unique method of case ascertainment, the
prevalence rate of definite epilepsy (cases under
treatment) was 1.2% in the present population sam-
ple. Although these findings were derived from a
limited number of individuals, they highlight pro-
blems in case definitions and ascertainment which
may hamper the comparison between various stu-
dies. In Forsgren’s multisource, population-based
study from a Swedish county,7 the prevalence in
adults was less than half as high (5.5/1000). This
figure was also based on at least one unprovoked
seizure during the last 5 years or treatment with
AEDs for epilepsy during the preceding year. The
figure from rural Iceland was similar (5.5/1000
above age 25), although slightly different criteriawere used.8 In a recent county-based survey from
the same part of Norway as the present study, the
mean prevalence was 8.2/1000 in selected age-
groups from 31 to 76 years.9 However, information
collected by questionnaires could only partly be
medically confirmed. Lower rates have been found
in Southern Italy, the lowest in the Aeolian Islands.10
Active epilepsy was identified in 3.1/1000 (3.5/1000
when including cases in remission with treatment).
The low figures have been interpreted as partly due
to concealment of the diagnosis causing under-
ascertainment. Accordingly, our findings suggest
that the prevalence of epilepsy may be higher than
reflected in various other studies.
The present investigation does not comprise the
entire population of the Va˚ga˚ community. It aims at
assessing the prevalence of epilepsy in a segment of
the inhabitants characterized by a relatively stable
and low risk for epilepsy. High-risk groups for epi-
lepsy, such as elderly people and individuals with
cognitive deficits, were excluded from this survey,
which was based on self-reporting. Non-participa-
tion might possibly be associated with milder
degrees of brain dysfunction than learning disability
or dementia, which may have been related to epi-
lepsy. The fact that participants were invited for an
epidemiological study of headache, is a potential
bias, as studies have shown an association between
headaches and epilepsy, particularly between
migraine and epilepsy.11—13 A lower prevalence of
headaches as well as seizures in individuals who did
not show interest in the study is possible. However,
an essential influence on the results is improbable
since the participation of the target population was
extremely high (88.6%).
Most epidemiological studies of epilepsy are
based on multiple sources, first of all on patients
attending special clinics or other treatment or diag-
nostic facilities. Studies based on less specialized
levels may comprise larger parts of the population,
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most direct method is the individual interview or
door-to-door survey. This approach can seldom be
employed due to the large patient number needed,
the time consumption and costs required, as well as
problems concerning the definition of the target
population14 and the medical verification of the
diagnosis. The strength of the present study design
is that many of these problems largely were over-
come. We believe that the health care system of
rural Norway provides a suitable background for this
kind of investigation. Va˚ga˚ has a relatively stable
population and is served by one single government-
run primary health care centre. The only neurolo-
gical service for the area is provided by the County
Hospital in Lillehammer. Relevant medical back-
ground information was available or could be col-
lected for all subjects who had been examined for
possible epileptic seizures. However, several weak-
nesses are apparent. A random error due to the
small sample size is possible and the representa-
tiveness of the area in relation to the entire country
may be questioned, as people with handicaps such
as epilepsy may tend to accumulate in their rural
home communities.
Nevertheless, the present survey calls attention
to some problematic issues in epidemiological stu-
dies in epilepsy. Which patients should be included
in estimates of epilepsy prevalence? This has dif-
fered in the past,1 a fact which makes it difficult to
compare various studies.8,9 ‘‘Active epilepsy’’4 is an
ambiguous term. It is evident that the number of
patients with a 5-year remission is influenced by the
quality of health care and by patient compliance.
Active epilepsy does not include all patients with an
enduring epileptic condition. E.g., patients with a
history of an unsuccessful discontinuation of AEDs
more than 5 years ago are left out from the pre-
valence of active epilepsy (patients 1 and 5,
Table 3). It also excludes most patients with idio-
pathic generalized epilepsy of more than 5 years
duration (patients 2, 4 and 5, Table 3), including
juvenile myoclonic epilepsy, in spite of the fact that
many of these patients usually need life-long treat-
ment to avoid recurrence.15 The great majority of
patients with idiopathic generalized epilepsy
achieve seizure freedom with appropriate treat-
ment.16 Thus, only adult patients with relatively
new onset idiopathic generalized epilepsy are
usually included as cases of active epilepsy. Many
patients with idiopathic generalized epilepsy har-
bour a persistent inherent predisposition to sei-
zures, but no such subjects were represented
among our active cases (Table 2). In contrast, in a
recent study from Tanzania, seizures were categor-
ized as generalized in 70%, although the epilepsysyndromes could not be accurately classified due to
limited access to diagnostic tools.14
Hence, reported prevalence rates of active epi-
lepsy are not only determined by the underlying
epileptic disorder. Seizure control in subjects with
epilepsy is dependent on geographical, socio-eco-
nomic and cultural differences. The patients’ level
of knowledge about their disorder and its manage-
ment is essential for treatment compliance and
behaviour in relation to seizure precipitants. The
standard of care and the access to treatment
facilities are crucial. In addition, traditions and
costs are factors which influence the duration of
treatment in patients in remission. The Norwegian
reimbursement practice of AEDs may increase the
number of patients with epilepsy under treatment,
as an economical motivation for patients to stop
treatment is negligible. The term, prevalence,
should always be clearly delineated in relation
to epilepsy. The present two-staged method with
an initial screening interview and a subsequent
detailed epileptological evaluation of subjects
who acknowledged possible epileptic seizures,
warrants a high sensitivity and specificity. The fact
that more than 50% of subjects who acknowledged
the possibility of epileptic manifestations,
appeared to have had other episodic symptoms,
may reflect a low level of knowledge about epi-
lepsy in the society. Surveillances exclusively rely-
ing on self-reporting may be seriously biased by
low specificity.
In conclusion, our findings indicate that the pre-
valence of definite epilepsy (cases under treatment)
exceeds 1.2% in a small community in rural Norway.
Further analyses will be undertaken to explore the
association between migraine and seizure disorders
in this population.References
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